PARIS--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced results from an exploratory Phase II study of 56 individuals that suggested that ORENCIA® (abatacept), a prescription drug for adults with moderate to severe rheumatoid arthritis (RA), may delay the development of RA in people with undifferentiated inflammatory arthritis (UA). ORENCIA is not indicated for people with UA. In addition, further studies in larger patient populations of UA are required to validate these findings. The results were presented at the Annual Congress of the European League Against Rheumatism (EULAR), held in Paris, France, from June 11 to June 14.
